Belite Bio to Participate in the BTIG Ophthalmology Day

Rhea-AI Summary

Belite Bio, Inc. (NASDAQ: BLTE) to Participate in BTIG Ophthalmology Day Event

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that management will participate in a fireside chat at the BTIG Ophthalmology Day on Monday, November 27, 2023, at 3:00 p.m. ET.

The Belite management team will be participating in one-on-one meetings at the event. Investors interested in meeting with Belite at the conference should contact their BTIG representative.

About Belite Bio
About Belite Bio Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease and geographic atrophy in advanced dry age-related macular degeneration, in addition to specific metabolic diseases. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contacts:

Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

FAQ

What is Belite Bio, Inc. focused on?

Belite Bio, Inc. is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases with significant unmet medical needs.

When will the fireside chat take place?

The fireside chat will take place on Monday, November 27, 2023, at 3:00 p.m. ET.

How can investors schedule a meeting with Belite at the conference?

Investors interested in meeting with Belite at the conference should contact their BTIG representative to schedule a one-on-one meeting with the Belite management team.